B-Raf IN 17
B-Raf IN 17 (Compound 8e) is a potent and orally active type II multi-kinase inhibitor. B-Raf IN 17 exhibits potent cellular-level suppression of BRAFWT, VEGFR-2, and FGFR-1 in A375 cell line, with IC50 values of 0.02, 0.18 and 1.65 μM, respectively. B-Raf IN 17 can be used for the research of cancer[1].
Product Specifications
UNSPSC
12352005
Target
FGFR; Raf; VEGFR
Type
Reference compound
Related Pathways
MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/b-raf-in-17.html
Solubility
10 mM in DMSO
Smiles
O=C(C1=CC=C2NC(C3=CC=CC=C3)=NC2=C1)N/N=C4C(NC5=C/4C=C(C=C5)Br)=O
Molecular Formula
C22H14BrN5O2
Molecular Weight
460.28
References & Citations
[1]Allam RM, et al. Benzimidazole-oxindole hybrids as multi-kinase inhibitors targeting melanoma. Bioorg Chem. 2024 Feb 26;146:107243.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog